These three names get used as if they were interchangeable. They are not, and the difference is easier to hold in your head than most write-ups make it sound. Count the receptors.
Semaglutide acts at one. Tirzepatide acts at two. Retatrutide acts at three. Almost everything else about how they compare follows from that.
Retatrutide vs tirzepatide vs semaglutide in 60 seconds
- Semaglutide acts on one receptor (GLP-1). It has the deepest research base.
- Tirzepatide acts on two (GLP-1 and GIP). It beat semaglutide head to head in SURMOUNT-5.
- Retatrutide acts on three (GLP-1, GIP and glucagon). It has the biggest results so far and the least data.
- More receptors is not automatically better: side effects are similar across the class and the newest compound has the shortest record.
The short version
- Semaglutide acts at the GLP-1 receptor only. It has the most published research of the three, and it is an approved medicine in many countries under several brand names.
- Tirzepatide acts at GLP-1 and GIP. It was the first compound to combine both in one molecule, and it is also an approved medicine in a number of countries.
- Retatrutide acts at GLP-1, GIP and the glucagon receptor. It produced the largest average weight loss of the three in its trials, and it is still investigational, with Lilly saying it plans to file for approval in the first quarter of 2027.

Semaglutide: one receptor
GLP-1 is a gut hormone released after eating. It signals fullness, slows the rate at which the stomach empties, and increases insulin release when blood glucose is high. Semaglutide is a modified version of it, built to last about a week in circulation instead of a few minutes.
Because it was first to market at scale, it has by far the deepest research base of the three. In the STEP-1 trial, participants lost an average of 14.9% of their body weight over 68 weeks. When people talk about the class as a whole, most of what they are actually describing was learned from semaglutide.
Tirzepatide: two receptors
GIP is the second incretin hormone, the less famous partner of GLP-1. It is involved in how the body handles nutrients after a meal and in insulin release. For years it was not obvious that adding it would help. Tirzepatide was the compound that tested the idea in one molecule.
It did. In SURMOUNT-1, the highest dose produced an average weight loss of 20.9% over 72 weeks, and in SURMOUNT-5, a head-to-head trial in adults with obesity, tirzepatide averaged 20.2% weight loss at 72 weeks against 13.7% for semaglutide. That result is the main reason the field moved towards combining receptors rather than simply making GLP-1 compounds stronger.
Retatrutide: three receptors
Retatrutide keeps GLP-1 and GIP and adds the glucagon receptor. That third arm is the interesting part, because glucagon does something the other two do not. It is associated with energy expenditure and with the liver releasing and burning stored energy. The first two receptors are mostly about eating less. The third is about using more.
The phase two results drew a lot of attention for exactly that reason: an average weight loss of 24.2% at 48 weeks on the highest dose. In May 2026 Lilly announced results from the first phase three trial, TRIUMPH-1. On the highest dose, people who stayed on treatment lost an average of 28.3% of their body weight at 80 weeks, or about 25% when everyone who started is counted. Lilly has said it plans to submit to the FDA in the first quarter of 2027, so for now retatrutide remains investigational and is not yet approved by SAHPRA or any other regulator. We cover the muscle side of fast weight loss in retatrutide and tesamorelin.
For how that unfolded over the 48 weeks, see retatrutide week by week: what the trials reported.

Why more receptors is not automatically better
It is tempting to read the list as a ranking: one, two, three, so three wins. The research does not support treating it that simply.
The side effects reported across the whole class are largely the same: nausea, vomiting, diarrhoea and reduced appetite, most noticeable when the amount is increased. The glucagon arm adds its own considerations. In the retatrutide trials, heart rate rose in a way that depended on how much was given, and that is the sort of detail that matters more than a headline percentage.
More receptors also means more ways for things to interact, and fewer years of data. Semaglutide has the longest record. Retatrutide has the shortest.
A question that follows from this one: if weight comes off this fast, what happens to muscle? We cover that, and the idea of pairing retatrutide with tesamorelin, in retatrutide and tesamorelin: can you lose fat without losing muscle?
A note on comparing prices
Price per milligram is the honest way to compare two options of the same compound. It is not a fair way to compare different compounds, because they are not used in the same amounts. Semaglutide is typically handled in much smaller quantities than tirzepatide or retatrutide, so a lower total milligram figure on a semaglutide pen does not mean it is poorer value.
For like-for-like comparisons, our retatrutide price page and tirzepatide price page list every option we carry with the price per milligram worked out. Our semaglutide option is the iZempic 5mg pen.
Where they stand in South Africa
The branded, approved versions of semaglutide and tirzepatide are prescription medicines here. The options we supply are not those branded products. They are research compounds, supplied for research use only and are not registered medicines, and none of them has been evaluated by SAHPRA. Our piece on whether peptides are legal in South Africa goes through what that means.
So which is which?
If you remember one thing, make it the receptor count. Semaglutide is the one with the long track record. Tirzepatide added a second receptor and outperformed it in direct comparisons. Retatrutide added a third, which is why it gets talked about as the next step, and why it also has the least data behind it.
Questions people ask
How many receptors does each one act on?
Semaglutide acts on one (GLP-1), tirzepatide on two (GLP-1 and GIP) and retatrutide on three (GLP-1, GIP and glucagon).
Did tirzepatide beat semaglutide head to head?
In SURMOUNT-5, tirzepatide averaged 20.2% weight loss at 72 weeks against 13.7% for semaglutide in adults with obesity.
Is retatrutide approved?
No. It is still investigational, and Lilly has said it plans to file with the FDA in the first quarter of 2027. It is not approved by SAHPRA or any other regulator.
Are the compounds you supply the branded medicines?
No. The branded, approved versions are prescription medicines. What we supply are research compounds, for research use only, and they are not registered medicines.
Sources
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36.
- Eli Lilly and Company. Retatrutide TRIUMPH-1 phase 3 results, press release, 21 May 2026 (the 28.3% figure is the efficacy estimand, for people who stayed on treatment).
Related reading: slimming injections in South Africa.
Every retatrutide and tirzepatide option we stock is compared on the retatrutide and tirzepatide price pages. If the vial side of things is new to you, start with how to reconstitute a peptide vial.

